You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四環醫藥(0460.HK):軒竹生物1類新藥吡羅西尼II期研究結果投稿被2023年ASCO年會接受
格隆匯 04-14 12:37

格隆匯4月14日丨四環醫藥(00460.HK)董事會欣然宣佈,集團旗下非全資附屬公司軒竹生物科技股份有限公司(“軒竹生物”)根據在研1類新藥吡羅西尼(Birociclib,XZP-3287 CDK4/6(細胞週期依賴性激酶4和6)抑制劑)(“吡羅西尼”)II期研究結果,於2023年2月10日向2023年ASCO (American Society of Clinical Oncology,美國臨牀腫瘤學會)年會進行投稿,題目為“A multicenter,single-arm,open-label trial of Birociclib, a CDK4/6 inhibitor,as a single agent,in patients with refractory HR+/HER2-metastatic breast cancer”。目前已接到通知,投稿將於2023年6月4日在Poster Session (海報論文)展示。

此次投稿內容主要包括臨牀研究設計,臨牀研究結果(藥物暴露、有效性和安全性結果)。投稿闡述了吡羅西尼單藥治療的療效優勢,反映出產品的差異化特點和臨牀價值。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account